Experiencia en mundo real con el uso de upadacitinib en inducción para enfermedad inflamatoria intestinal en Colombia: uparecol-induction
DOI:
https://doi.org/10.47892/rgp.2025.453.1904Palabras clave:
Enfermedades Inflamatorias del Intestino, Inhibidores de las Cinasas Janus, Upadacitinib, Terapéutica, Manejo de la Enfermedad, Efectos Colaterales y Reacciones Adversas Relacionados con MedicamentosResumen
Introducción: No existen estudios sobre la eficacia y seguridad de upadacitinib para la Enfermedad Inflamatoria Intestinal (EII) en Latinoamérica. Objetivo: Este estudio busca describir su eficacia y seguridad en la fase de inducción en pacientes con EII moderada/ grave. Materiales y métodos: Estudio observacional descriptivo multicéntrico en pacientes con EII que recibieron upadacitinib en inducción entre julio de 2024 y enero de 2025. Resultados: Se incluyeron 26 pacientes, 53,8% mujeres, edad media 41,5 años (rango 18,1-70,4; DE 17,5). El 61,5% tenía colitis ulcerosa (CU) y 38.5% enfermedad de Crohn (EC), con un tiempo medio de diagnóstico de 6,4 años. En CU, 62,5% lograron respuesta clínica, 37,5% remisión clínica y 56,3% remisión bioquímica. En EC, 70% lograron respuesta clínica, 20% remisión clínica y 50% remisión bioquímica. Nueve de 16 pacientes con CU (56,3%) y 3 de 10 con EC (30%) lograron remisión clínica de la frecuencia de las heces y el dolor abdominal. En CU hubo una tendencia hacia mayor eficacia en urgencia defecatoria (OR 2,87; IC 95%: 0,53-18,25; p=0,19). De los 12 pacientes con manifestaciones extraintestinales (MEI), 75% presentaron remisión. Se reportaron eventos adversos en 5 pacientes (19,3%): tres casos de acné, una infección leve y una infección severa. Conclusiones: Este primer estudio latinoamericano con upadacitinib en EII demuestra eficacia y seguridad en pacientes con actividad moderada a grave.
Descargas
Métricas
Citas
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389(10080):1741-55. doi: 10.1016/ S0140-6736(16)31711-1.
Herrera-deGuise C, Serra-Ruiz X, Lastiri E, Borruel N. JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases. Front Med (Lausanne). 2023;10:1089099. doi: 10.3389/fmed.2023.1089099.
Caballero-Mateos AM, Cañadas-De la Fuente GA. Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management. World J Gastroenterol. 2024;30(35):3942-53. doi: 10.3748/wjg.v30.i35.3942.
Faggiani I, D’Amico F, Bernardi F, Bencardino S, Allocca M, Furfaro F, et al. Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn’s disease. Expert Opin Drug Metab Toxicol. 2024;20(5):297-305. doi: 10.1080/17425255.2024.2349711.
Dignass A, Esters P, Flauaus C. Upadacitinib in Crohn’s disease. Expert Opin Pharmacother. 2024;25(4):359-70. doi: 10.1080/14656566.2024.2333964.
Núñez P, Quera R, Yarur AJ. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases. Drugs. 2023;83(4):299-314. doi: 10.1007/s40265-023-01840-5.
Food and Drug Administration. Rinvoq. Label via DailyMed. FDA; 2024.
Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113-28. doi: 10.1016/S0140-6736(22)00581-5.
Sandborn WJ, Ghosh S, Panes J, Schreiber S, D’Haens G, Tanida S, et al. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology. 2020;158(8):2139-2149.e14. doi: 10.1053/j.gastro.2020.02.030.
Loftus EV Jr, Panés J, Lacerda AP, Peyrin-Biroulet L, D’Haens G, Panaccione R, et al. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2023;388(21):1966- 1980. doi: 10.1056/NEJMoa2212728.
Balderramo D, Quaresma AB, Olivera PA, Savio MC, Villamil MPG, Panaccione R, et al. Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America. Lancet Gastroenterol Hepatol. 2024;9(3):263-72. doi: 10.1016/ S2468-1253(23)00284-4.
Instituto Nacional de Vigilancia de Medicamentos y Alimentos. Medicamentos y productos biológicos. Bogotá: INVMA; 2024. Disponible en: https://www.invima.gov.co/sites/default/files/ medicamentos-productos-biolog
Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut. 2022;71(10):1976-87. doi: 10.1136/gutjnl-2021-326390.
Farkas B, Bessissow T, Limdi JK, Sethi-Arora K, Kagramanova A, Knyazev O, et al. Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study. J Clin Med. 2024;13(24):7804. doi: 10.3390/jcm13247804.
Akiyama S, Shimizu H, Tamura A, Yokoyama K, Sakurai T, Kobayashi M, et al. Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A RealWorld Multicentre Study in Japan. Aliment Pharmacol Ther. 2025;61(3):524-537. doi: 10.1111/apt.18406.
García MJ, Brenes Y, Vicuña M, Bermejo F, Sierra-Ausín M, Vicente R, et al. Persistence, Effectiveness, and Safety of Upadacitinib in Crohn’s Disease and Ulcerative Colitis in Real Life: Results From a Spanish Nationwide Study (Ureal Study). Am J Gastroenterol. 2024;120(7):1593-1604. doi: 10.14309/ ajg.0000000000003243.
Hosomi S, Nishida Y, Fujiwara Y. Efficacy of Upadacitinib As a Second-line JAK Inhibitor in Ulcerative Colitis: A Case Series. Intern Med. 2024;63(13):1882-5. doi: 10.2169/ internalmedicine.2653-23.
Odah T, Karime C, Desai A, Picco MF, Kinnucan JA, Hashash JG, et al. Response to Upadacitinib in Patients with Inflammatory Bowel Disease Previously Treated with Tofacitinib. Dig Dis Sci. 2024;69(10):3911-3919. doi: 10.1007/s10620-024-08630-3.
Zheng D yu, Wang Y nuo, Huang YH, Jiang M, Dai C. Effectiveness and safety of upadacitinib for inflammatory bowel disease: A systematic review and meta-analysis of RCT and real-world observational studies. Int Immunopharmacol. 2024;126:111229. doi: 10.1016/j.intimp.2023.111229.
Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384-413. doi: 10.14309/ ajg.0000000000000152.
Lichtenstein GR, Loftus E V., Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol. 2018;113(4):481-517. doi: 10.1038/ajg.2018.27.
Kawakatsu S, Zhu R, Zhang W, Tang MT, Lu T, Quartino AL, et al. A longitudinal model for the Mayo Clinical Score and its subcomponents in patients with ulcerative colitis. J Pharmacokinet Pharmacodyn. 2022;49(2):179-90. doi: 10.1007/s10928-021- 09789-2.
Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s Disease Activity Index: National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70(3):439-44.
Khanna R, Zou GY, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, et al. Responsiveness of Endoscopic Indices of Disease Activity for Crohn’s Disease. Am J Gastroenterol. 2017;112(10):1584- 92. doi: 10.1038/ajg.2016.580.
Panaccione R, Danese S, Zhou W, Klaff J, Ilo D, Yao X, et al. Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2024;59(3):393-408. doi: 10.1111/apt.17816.
Vuitton L, Peyrin-Biroulet L, Colombel JF, Pariente B, Pineton de Chambrun G, Walsh AJ, et al. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther. 2017;45(6):801-13. doi: 10.1111/apt.13948.
Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: Looking beyond symptoms. Curr Gastroenterol Rep. 2013;15(3):315. doi: 10.1007/s11894-013-0315-7.
Panaccione R, Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ. Evolving definitions of remission in Crohn’s disease. Inflamm Bowel Dis. 2013;19(8):1645-53. doi: 10.1097/ MIB.0b013e318283a4b3.
Guillo L, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, et al. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. Lancet Gastroenterol Hepatol. 2022;7(3):254- 61. doi: 10.1016/S2468-1253(21)00297-1.
Falloon K, Cohen B, Ananthakrishnan AN, Barnes EL, Bhattacharya A, Colombel JF, et al. A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55(9):1179-91. doi: 10.1111/apt.16853.
Peyrin-Biroulet L, Panaccione R, Louis E, Atreya R, Rubin DT, Lindsay JO, et al. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure. Clin Gastroenterol Hepatol. 2024;22(10):2096-106. doi: 10.1016/j.cgh.2024.02.026.
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4. doi: 10.1001/jama.2013.281053.
Liu Y, Song XM, Xiang LY, Tan W, Zou M, Guo H. Rapid Remission With Upadacitinib in a Child With Refractory Crohn’s Disease and ATM Mutation: A Case Report. Curr Ther Res Clin Exp. 2024;101:100756. doi: 10.1016/j.curtheres.2024.100756.
Spencer EA, Bergstein S, Dolinger M, Pittman N, Kellar A, Dunkin D, et al. Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024;30(11):2057-2063. doi: 10.1093/ibd/ izad300.
Collen LV. Rapid Clinical Remission With Upadacitinib in a Pediatric Patient With Refractory Crohn’s Disease. Inflamm Bowel Dis. 2023;29(7):1175-6. doi: 10.1093/ibd/izad048.
Friedberg S, Choi D, Hunold T, Choi NK, Garcia NM, Picker EA, et al. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn’s Disease: Prospective Real-World Experience. Clin Gastroenterol Hepatol. 2023;21(7):1913-1923.e2. doi: 10.1016/j.cgh.2023.03.001.
Kulyk A, Shafer LA, Graff LA, Stone J, Witges K, Targownik LE, et al. Urgency for bowel movements is a highly discriminatory symptom of active disease in persons with IBD (the Manitoba Living with IBD study). Aliment Pharmacol Ther. 2022;56(11– 12):1570-80. doi: 10.1111/apt.17241.
Ghosh S, Gonzalez YS, Zhou W, Clark R, Xie W, Louis E, et al. Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates with Quality of Life Improvements in Patients with Moderate to Severe Ulcerative Colitis. J Crohn’s Colitis. 2021;15(12):2022-30. doi: 10.1093/ecco-jcc/jjab099.
Colombel JF, Hisamatsu T, Atreya R, Bresso F, Thin L, Panaccione R, et al. Upadacitinib Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy. Clin Gastroenterol Hepatol. 2024;22(8):1668-77. doi: 10.1016/j.cgh.2024.02.027.
Mohamed MEF, Klünder B, Lacerda AP, Othman AA. Exposure– Response Analyses for Upadacitinib Efficacy and Safety in the Crohn’s Disease CELEST Study and Bridging to the Extended-Release Formulation. Clin Pharmacol Ther. 2020;107(3):639- 49. doi: 10.1002/cpt.1668.
Sandborn WJ, Feagan BG, Loftus E V., Peyrin-Biroulet L, Van Assche G, D’Haens G, et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease. Gastroenterology. 2020;158(8):2123-2138.e8. doi: 10.1053/j. gastro.2020.01.047.
Suzuki K, Akiyama M, Inokuchi H, Saito K, Hanaoka H, Kaneko Y. Successful treatment of Crohn’s disease-related peripheral spondyloarthritis with upadacitinib: two case reports and case-based review. Rheumatol Int. 2024;44(12):3127-3133. doi: 10.1007/s00296-024-05735-w.
Napolitano M, D’amico F, Ragaini E, Peyrin-Biroulet L, Danese S. Evaluating Upadacitinib in the Treatment of Moderateto-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy. Drug Des Devel Ther. 2022;16:1897-913. doi: 10.2147/DDDT.S340459.
Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, et al. Safety profile of upadacitinib in patients at risk of cardiovascular disease: Integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023;82(9):1130-41. doi: 10.1136/ard-2023-223916.
Yuan J, Lu HX, Zuo X, Yin L, Pu Y, Zhang J. Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database. Pharmacoepidemiol Drug Saf. 2024;33(10):e70030. doi: 10.1002/pds.70030.
Martinez J, Manjaly C, Manjaly P, Ly S, Zhou G, Barbieri J, et al. Janus Kinase Inhibitors and Adverse Events of Acne: A Systematic Review and Meta-Analysis. JAMA Dermatology. 2023;159(12):1339-45. doi: 10.1001/jamadermatol.2023.3830
.47. Sun C, Su Z, Zeng YP. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis. Inflamm Res. 2023;72(9):1861-71. doi: 10.1007/s00011-023-01789-x.
Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-tosevere atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022;87(4):784-91. doi: 10.1016/j. jaad.2022.06.012.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2025 Viviana Parra-Izquierdo, Juan Sebastián Frías-Ordoñez, Fabio Leonel Gil-Parada, William Otero-Regino, Jonathan Barreto Perez, German Manuel Tovar Fierro, Fabian Eduardo Puentes-Manosalva, Pedro Eduardo Cuervo Pico, María Teresa Galiano, Javier Riveros, Alvaro Andrés Gomez-Venegas, Carlos Andrés Medrano Almanza, Daniel Perea, Manuel Ballesteros, Carlos Augusto Cuadros Mendoza, Cristian Florez-Sarmiento
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Revista de Gastroenterología del Perú by Sociedad Peruana de Gastroenterología del Perú is licensed under a Licencia Creative Commons Atribución 4.0 Internacional..
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
2022 